These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31933417)

  • 1. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Sia TY; Manning-Geist BL; Ehmann S; Lavery JA; Luardo C; Praiss A; Iasonos A; Sonoda Y; Grisham RN; Liu YL; Broach V; Zivanovic O; Long Roche K; Gardner GJ; Chi DS
    Gynecol Oncol; 2023 Sep; 176():69-75. PubMed ID: 37454565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
    Zou RY; Yuan L; Chen M; Yao LQ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis.
    Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2021 Aug; 162(2):345-352. PubMed ID: 34045053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients.
    So M; Miyamoto T; Murakami R; Abiko K; Hamanishi J; Baba T; Mandai M
    J Gynecol Oncol; 2019 Nov; 30(6):e100. PubMed ID: 31576692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience.
    Gallotta V; Conte C; Giudice MT; Nero C; Vizzielli G; Gueli Alletti S; Cianci S; Lodoli C; Di Giorgio A; De Rose AM; Fagotti A; Scambia G; Ferrandina G
    J Minim Invasive Gynecol; 2018; 25(4):644-650. PubMed ID: 29081384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.
    Paik ES; Lee YY; Kim TJ; Choi CH; Lee JW; Kim BG; Bae DS
    J Gynecol Oncol; 2016 May; 27(3):e24. PubMed ID: 27029745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
    Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
    J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
    Merlo S; Besic N; Drmota E; Kovacevic N
    Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Ehmann S; Lam C; Zhou Q; Iasonos A; Grisham RN; Tew WP; O'Cearbhaill RE; Long Roche K; Zivanovic O; Sonoda Y; Chi DS; Gardner GJ
    Gynecol Oncol; 2024 Jul; 186():104-109. PubMed ID: 38640773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.